BofA Securities stays Buy on Catalyst Pharma (CPRX) amid Angelini acquisition interest reports

April 27, 2026 4:15 PM

BofA Securities analyst Jason M. Gerberry reiterated a Buy rating and $35.00 price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX)The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found